Zenith Drugs Ltd
Incorporated in 2000, Zenith Drugs Limited is a pharmaceutical company specializing in manufacturing and trading medicines, including generic drugs.[1]
- Market Cap ₹ 154 Cr.
- Current Price ₹ 90.0
- High / Low ₹ 114 / 52.8
- Stock P/E 14.0
- Book Value ₹ 36.3
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -30.0%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 78 | 72 | 92 | 115 | 132 | |
| 71 | 64 | 85 | 105 | 115 | |
| Operating Profit | 7 | 7 | 7 | 9 | 17 |
| OPM % | 9% | 10% | 8% | 8% | 13% |
| 0 | 0 | 1 | 1 | 1 | |
| Interest | 1 | 1 | 2 | 2 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 5 | 5 | 4 | 7 | 13 |
| Tax % | 30% | 33% | 27% | 27% | 28% |
| 3 | 3 | 3 | 5 | 10 | |
| EPS in Rs | 5.56 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 22% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 53% |
| TTM: | 125% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 0 | 0 | 0 | 17 | 17 |
| Reserves | 6 | 9 | 12 | 45 | 45 |
| 12 | 15 | 17 | 24 | 24 | |
| 25 | 21 | 37 | 48 | 48 | |
| Total Liabilities | 44 | 47 | 66 | 134 | 134 |
| 6 | 9 | 10 | 11 | 11 | |
| CWIP | 3 | 0 | 0 | 4 | 4 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 35 | 37 | 56 | 119 | 119 | |
| Total Assets | 44 | 47 | 66 | 134 | 134 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 3 | -1 | 5 | |||
| -5 | -2 | -3 | |||
| 1 | 3 | -1 | |||
| Net Cash Flow | -0 | -0 | 1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Debtor Days | 119 | 119 | 128 | ||
| Inventory Days | 29 | 52 | 67 | ||
| Days Payable | 155 | 155 | 190 | ||
| Cash Conversion Cycle | -7 | 17 | 5 | ||
| Working Capital Days | 26 | 66 | 58 | ||
| ROCE % | 28% | 24% |
Documents
Announcements
-
Price movement
18 July 2024 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written …
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
17 July 2024 - Zenith Drugs Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Quarter Ended 30th June, 2024, F.Y. 2024-25
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
17 July 2024 - Zenith Drugs Limited has informed about Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th Jun 2024
-
Updates
11 June 2024 - Zenith Drugs Limited has informed regarding submission of financial results for the period ended 31-Mar-2024 in Machine Readable Form / Legible copy''.
-
Statement of deviation(s) or variation(s) under Reg. 32
30 May 2024 - Zenith Drugs Limited has informed about statement of deviation(s) or variation(s) under Reg. 32
Annual reports
No data available.
Product Portfolio[1]
ORS Powder;
Liquid Orals;
Ointments;
Liquid Externals;
Capsules